Joel Greenblatt’s Adaptive Biotechnologies ADPT Stock Holding History

Joel Greenblatt’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.6M	Sell	74,732 -16,013	-18%	-$245K	﹤0.01%	1217
2026 Q1	$1.26M	Sell	90,745 -50,011	-36%	-$797K	﹤0.01%	1244
2025 Q4	$2.29M	Buy	140,756 +13,692	+11%	+$223K	0.01%	999
2025 Q3	$1.9M	Buy	127,064 +55,177	+77%	+$672K	0.01%	1018
2025 Q2	$837K	Buy	71,887 +61,194	+572%	+$556K	0.01%	1189
2025 Q1	$79.4K	Buy	+10,693	New	+$82.2K	﹤0.01%	1517
2023 Q3	–	Sell	-16,073	Closed	-$108K	–	1315
2023 Q2	$108K	Sell	16,073 -30,210	-65%	-$225K	﹤0.01%	1268
2023 Q1	$409K	Buy	46,283 +14,616	+46%	+$129K	0.01%	1029
2022 Q4	$242K	Sell	31,667 -19,816	-38%	-$154K	0.01%	1093
2022 Q3	$367K	Sell	51,483 -723	-1%	-$6.81K	0.01%	926
2022 Q2	$422K	Buy	+52,206	New	+$459K	0.01%	839

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Joel Greenblatt's ADPT Position: Q2 2026 in Review

Joel Greenblatt reduced its Adaptive Biotechnologies (ADPT) stake by 18% in Q2 2026, selling an estimated $245K and leaving 74,732 shares worth $1.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1217.

Joel Greenblatt first reported a position in ADPT in Q2 2022 and has held it in 11 quarters since. The position peaked at $2.29M in Q4 2025. 298 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

Joel Greenblatt held 74,732 shares of Adaptive Biotechnologies worth $1.6M as of Q2 2026.
Joel Greenblatt sold 16,013 Adaptive Biotechnologies shares in Q2 2026, an estimated $245K.
Adaptive Biotechnologies made up ﹤0.01% of Joel Greenblatt's portfolio in Q2 2026, its #1217 holding.
Joel Greenblatt first reported a position in Adaptive Biotechnologies in Q2 2022 and has held it in 11 quarters since.
Joel Greenblatt's Adaptive Biotechnologies position peaked at $2.29M in Q4 2025.
298 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.